anti-B7H3 antibody-drug conjugate (AstraZeneca/National Cancer Institute)

N/A

Report date: 2025/03/14 16:17:18

Base Information

Drug Nameanti-B7H3 antibody-drug conjugate (AstraZeneca/National Cancer Institute)
Drug Alias Nameanti-B7H3 antibody-pyrrolobenzodiazepine conjugate (AstraZeneca/National Cancer Institute)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)Biologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionCD276 antigen modulators
TargetsCD276 antigen
Therapy Area/IndicationsProstatic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesNational Cancer Institute
China Registration ClassN/A

Develop Information

Active CompaniesAstrazeneca PlcNational Cancer Institute
Inactive CompaniesN/A
Active IndicationsProstatic Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A